| Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panel S Kleinman, T Caulfield, P Chan, R Davenport, J McFarland, ... Transfusion 44 (12), 1774-1789, 2004 | 935 | 2004 |
| Science communication reconsidered T Bubela, MC Nisbet, R Borchelt, F Brunger, C Critchley, E Einsiedel, ... Nature biotechnology 27 (6), 514-518, 2009 | 579 | 2009 |
| Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers TM Bubela, TA Caulfield Cmaj 170 (9), 1399-1407, 2004 | 400 | 2004 |
| Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine D Lau, U Ogbogu, B Taylor, T Stafinski, D Menon, T Caulfield Cell stem cell 3 (6), 591-594, 2008 | 371 | 2008 |
| Research ethics recommendations for whole-genome research: consensus statement T Caulfield, AL McGuire, M Cho, JA Buchanan, MM Burgess, U Danilczyk, ... PLoS biology 6 (3), e73, 2008 | 301 | 2008 |
| Research ethics and the challenge of whole-genome sequencing AL McGuire, T Caulfield, MK Cho Nature Reviews Genetics 9 (2), 152-156, 2008 | 266 | 2008 |
| Deflating the genomic bubble JP Evans, EM Meslin, TM Marteau, T Caulfield Science 331 (6019), 861-862, 2011 | 241 | 2011 |
| Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines GQ Daley, I Hyun, JF Apperley, RA Barker, N Benvenisty, AL Bredenoord, ... Stem cell reports 6 (6), 787-797, 2016 | 209 | 2016 |
| DNA databanks and consent: a suggested policy option involving an authorization model T Caulfield, REG Upshur, A Daar BMC medical ethics 4, 1-4, 2003 | 197 | 2003 |
| Science and the sources of hype T Caulfield, C Condit Public Health Genomics 15 (3-4), 209-217, 2012 | 177 | 2012 |
| Marketing of unproven stem cell–based interventions: a call to action D Sipp, T Caulfield, J Kaye, J Barfoot, C Blackburn, S Chan, M De Luca, ... Science translational medicine 9 (397), eaag0426, 2017 | 171 | 2017 |
| Direct-to-consumer genetic testing: perceptions, problems, and policy responses T Caulfield, AL McGuire Annual review of medicine 63, 23-33, 2012 | 149 | 2012 |
| Race and ancestry in biomedical research: exploring the challenges T Caulfield, SM Fullerton, SE Ali-Khan, L Arbour, EG Burchard, ... Genome medicine 1, 1-8, 2009 | 148 | 2009 |
| A review of the key issues associated with the commercialization of biobanks T Caulfield, S Burningham, Y Joly, Z Master, ... Journal of Law and the Biosciences 1 (1), 94-110, 2014 | 143 | 2014 |
| Biotechnology and the popular press: hype and the selling of science T Caulfield TRENDS in Biotechnology 22 (7), 337-339, 2004 | 143 | 2004 |
| Confronting stem cell hype T Caulfield, D Sipp, CE Murry, GQ Daley, J Kimmelman Science 352 (6287), 776-777, 2016 | 142 | 2016 |
| Evidence and anecdotes: an analysis of human gene patenting controversies T Caulfield, RM Cook-Deegan, FS Kieff, JP Walsh Nature biotechnology 24 (9), 1091-1094, 2006 | 141 | 2006 |
| Point-counterpoint. Ethics and genomic incidental findings. AL McGuire, S Joffe, BA Koenig, BB Biesecker, LB McCullough, ... Science (New York, NY) 340 (6136), 1047-1048, 2013 | 131 | 2013 |
| Biobanks and blanket consent: the proper place of the public good and public perception rationales T Caulfield King's Law Journal 18 (2), 209-226, 2007 | 123 | 2007 |
| Biobanks, consent and claims of consensus Z Master, E Nelson, B Murdoch, T Caulfield Nature Methods 9 (9), 885-888, 2012 | 119 | 2012 |
